

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/665,658	09/19/2003	Paula M. Jardieu	P1014R1C1D1C1	8846
9157	7590 11/17/2005		EXAMINER	
GENENTECH, INC.			HADDAD, MAHER M	
1 DNA WAY SOUTH SAN FRANCISCO, CA 94080		0	ART UNIT PAPER NUI	
	•		1644	

DATE MAILED: 11/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/665,658	JARDIEU ET AL.				
Office Action Summary	Examiner	Art Unit				
	Maher M. Haddad	1644				
The MAILING DATE of this communication ap	pears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING E - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 26 J	lanuary 2005.					
,	<u> </u>					
3) Since this application is in condition for allowa	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims		•				
4)⊠ Claim(s) 1-14 is/are pending in the application	n.					
4a) Of the above claim(s) is/are withdra	awn from consideration.					
5) Claim(s) is/are allowed.		•				
6) ☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>1-14</u> are subject to restriction and/or	election requirement.					
Application Papers	•					
9) The specification is objected to by the Examine	er.					
10)☐ The drawing(s) filed on is/are: a)☐ acc	cepted or b) \square objected to by the I	Examiner.				
Applicant may not request that any objection to the	e drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct	· •					
11) ☐ The oath or declaration is objected to by the E	xaminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	n priority under 35 U.S.C. § 119(a))-(d) or (f).				
, ,	ts have been received					
 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 						
3. Copies of the certified copies of the price						
application from the International Burea	•	· ·				
* See the attached detailed Office action for a list	t of the certified copies not receive	ed.				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate atent Application (PTO-152)				
 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date 	6) Other:	atom philodion (1 10-102)				

Application/Control Number: 10/665,658 Page 2

Art Unit: 1644

DETAILED ACTION

1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 1-7, drawn to a method of treating systemic lupus erythmatosus in a patient in need thereof comprising administering a humanized anti-CD11a antibody, classified in Class 424, subclass 133.1.
- II. Claims 8-14, drawn to a method of treating multiple sclerosis in a patient in need thereof comprising administering a humanized anti-CD11a antibody, classified in Class 424, subclass 133.1.
- 2. Groups I and II are different methods. Various methods of treating differ with respect to ingredients, method steps, and endpoints; therefore, each method is patentably distinct.
- 3. These inventions are distinct for the reasons given above. In addition, they have acquired a separate status in the art as shown by different classification and/or recognized divergent subject matter. Further, even though in some cases the classification is shared, a different field of search would be required based upon the structurally distinct products recited and the various methods of use comprising distinct method steps. Therefore restriction for examination purposes as indicated is proper. Further, a prior art search also requires a literature search. It is an undue burden for the examiner to search more than one invention.
- 4. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad whose telephone number is (571) 272-0845. The examiner can normally be reached Monday through Friday from 7:30 am to 4:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/665,658 Page 3

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

November 11, 2005

Maher Haddad, Ph.D. Patent Examiner

Maker Haddad

Technology Center 1600